Humacyte, Inc. Selling, General and Administrative Expense
Humacyte, Inc. (HUMA) reported Selling, General and Administrative Expense of $7.61 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-11-12
- Humacyte, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $7.61M, a 4.15% increase year-over-year.
- Humacyte, Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $7.81M, a 35.90% increase year-over-year.
- Humacyte, Inc. selling, general and administrative expense for the quarter ending 2025-03-31 was $8.14M, a 53.11% increase year-over-year.
- Humacyte, Inc. selling, general and administrative expense for the quarter ending 2024-09-30 was $7.31M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month |
|---|---|---|---|
| 2025-09-30 | $7.61M 10-Q · filed 2025-11-12 | $15.42M derived: sum of 2 quarters · filed 2025-11-12 | $23.55M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $7.81M 10-Q · filed 2025-08-11 | $15.95M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $8.14M 10-Q · filed 2025-05-13 | ||
| 2024-09-30 | $7.31M 10-Q · filed 2025-11-12 | $13.05M derived: sum of 2 quarters · filed 2025-11-12 | $18.37M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $5.75M 10-Q · filed 2025-08-11 | $11.06M 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $5.31M 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |